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Reperfusion with recombinant tissue plasminogen activator (tPA) sometimes causes catastrophic hem-
orrhagic transformation (HT) in the ischemic brain.  Consequently,  the application of tPA has been 
strictly limited.  Recent studies have indicated that matrix metalloproteinases (MMPs),  especially 
MMP-9,  play a critical role in blood brain barrier (BBB) disruption in the ischemic brain,  leading to 
brain edema and HT.  In the ischemic brain,  free radicals and exogenous tPA itself can trigger 
MMP-9 activation through several signaling pathways containing LDL receptor-related protein (LRP) 
and proteinase-activated receptor 1 (PAR1).  Therapeutic targeting of free radicals and MMP-9/t-PA 
related signaling pathways might be promising approaches to minimizing catastrophic HT in acute 
stroke patients.  We provide an overview of the available scientiﬁc reports to improve our understand-
ing of the mechanisms leading to HT,  and highlight recent progress in the development of new thera-
peutic strategies for preventing HT in the post-stroke brain.
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trokes are a major cause of death and result in 
a severe reduction in the quality of life.  If 
cerebral blood ﬂow is restored by tissue plasminogen 
activator (tPA),  ischemic brain damage can be amelio-
rated [1].  However,  since delayed reperfusion with 
tPA can cause hemorrhagic transformation (HT) [2],  
the application of tPA is strictly limited in a clinical 
setting.  An understanding of the mechanism underly-
ing HT and a new therapeutic strategy prohibiting HT 
are both needed.  In this paper,  we focus on therapeu-
tic approaches to vascular protection that can help 
prevent HT in the ischemic brain when treated with 
tPA.
Microvascular Integrity and MMPs
　 Cerebral microvascular integrity mainly depends on 
three components: the vascular wall formed by 
endothelial cells,  the blood brain barrier (BBB) pro-
vided by endothelial tight junctions,  and the basal 
membrane lining the endothelial cells [3] (Fig.  1).  
Recent studies indicated that matrix metalloprotei-
nases (MMPs),  especially MMP-9,  can play critical 
roles in BBB disruption in the ischemic brain [4].  
MMP-9 comprises a family of zinc endopeptidases,  
and cerebral vascular endothelial cells and inﬁltrating 
leukocytes are regarded as the main cellular sources 
of MMP-9 in the ischemic brain [5-7].  MMP-9 
knock-out mice showed a signiﬁcant reduction in BBB 
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disruption and brain edema,  and this eﬀect was asso-
ciated with reduced degradation of the MMP-9 sub-
strate of a tight junction protein,  ZO-1 [8].  Recent 
scientiﬁc papers have suggested that MMP-9 can dis-
rupt the BBB by degrading not only tight junction 
proteins but also basal membrane proteins (e.g.,  
ﬁbronectin,  laminin,  collagen,  and others),  thereby 
leading to BBB disruption,  brain edema,  and HT in 
the post-ischemic brain in animal models [9,  10].
MMP-9 Expression in Stroke Patients
　 By using gelatin zymography,  Clark et al.  reported 
that MMP-9 activity was markedly elevated in 
infarcted human brain tissue 2 days after an ischemic 
stroke [11].  Montaner et al.  reported that a high 
level of plasmatic MMP-9 expression in stroke 
patients could predict HT after thrombolysis [12].  A 
substrate of MMP-9,  ﬁbronectin,  has also been 
reported to be a useful biomarker for predicting HT 
[13].  Faster analytic methods for the above 2 bio-
markers are now required to develop a new strategy 
for predicting HT in routine clinical practice.
Free Radicals Activating MMP-9
　 Free radicals,  the fundamental mediators of reper-
fusion injury,  are generated soon after vessel occlu-
sion,  with explosive propagation after reperfusion in 
the ischemic brain [14].  Superoxide dismutase 
(SOD2) is the principal defense against the toxicity of 
free radicals,  and SOD2 knock-out mice exhibit a 
signiﬁcant increase in MMP-9 and a higher rate of 
brain hemorrhaging after middle cerebral artery 
occlusion (MCAO) [15],  indicating that the excess 
radicals can activate MMP-9,  inducing HT in the 
post-ischemic brain.
Exogenous tPA Activating MMP-9
　 Systemic administration of exogenous tPA ampli-
ﬁed MMP-9 levels in the ischemic rat brain.  
Perfusion of tPA resulted in the disruption of BBB 
and the degradation of a basal membrane protein,  
laminin,  in rat blood vessels [16].  In addition,  
MMP-9 expression,  infarct size,  and brain edema in 
tPA knock-out mouse were signiﬁcantly lower than in 
wild-type mice [17],  indicating that exogenous tPA 
can strongly increase the activity of MMP-9 in the 
brain.  MMP-9 can be activated by tPA via several 
molecular signaling pathways including the tPA-LRP 
and tPA-PAR1 pathways (Fig.  2).  The LDL recep-
tor-related protein (LRP) is a member of the LDL 
receptor gene family that binds several ligands,  such 
as tPA [18].  LRP is expressed in neurons and 
perivascular astrocytes [19],  and tPA can cross the 
BBB by LRP-mediated transcytosis [20].  tPA treat-
ment stimulates MMP-9 expression in cultured human 
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Fig. 1　 Schematic diagram of vascular unit that comprises endothelial cells,  astrocytes,  and pericytes.  MMP-9 is mainly derived from 
brain endothelial cells and inﬁltrating neutrophils in the acute phase of a stroke.  MMP-9 can degrade the basement membrane,  which links 
the endothelial cells,  and maintains the integrity of the vascular unit.
brain endothelial cells.  This eﬀect is dramatically 
reduced in endothelial cells treated with RNAi against 
LRP,  but was absent in LRP-deﬁcient MEF cells 
[21].  Moreover,  intraventricular injection of tPA 
into the mouse brain increased BBB permeability,  
although this eﬀect was blocked by LRP antagonists.  
These ﬁndings indicate that LRP signaling plays an 
important role in tPA-induced MMP-9 activation.  
Cheng et al.  reported that activated protein C (APC) 
could inhibit tPA-induced MMP-9 activation in the 
endothelium of an ischemic brain.  This inhibition was 
absent in protease-activated receptor 1 (PAR-1) 
knock-out mouse,  indicating that PAR1 is required 
for APC-mediated down-regulation of tPA-induced 
MMP-9 [22].
Therapeutic Strategy for Vascular Protection 
Inhibiting HT
　 The mechanism of the vascular unit disruption 
after ischemia and reperfusion with tPA has been 
extensively studied.  These results indicate that free 
radicals and MMP-9 are regarded as key regulators 
leading to the disruption of a vascular unit (Fig.  2).  
Therefore,  many research groups have tested various 
kinds of drugs or reagents against free radicals and 
MMP-9,  and some of them have been reported to be 
able to protect the vascular unit and inhibit HT 
(Table 1).
　 We used a spontaneously hypertensive rat model of 
MCAO and tested the eﬃcacy of a free radical scav-
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Table 1　 Scientiﬁc papers reporting reagents that can attenuate hemorrhagic cerebral infarction in animal models
Drug name Supposed mechanisms Animal model References
Imatinib
(PDGFR-α antagonist)
Suppressing PDGFR-α activation Mouse hemorrhagic cerebral infarction model Su et al. [28]
Activated protein C Suppressing the tPA-PAR1-MMP9 pathway Mouse hemorrhagic cerebral infarction model Cheng et al. [22]
Melatonin Suppressing MMP9 activity Rat hemorrhagic cerebral infarction model Hung et al. [29]
BB-94 (MMP9 inhibitor) Suppressing MMP9 activity Rat hemorrhagic cerebral infarction model Sumii et al. [30]
Minocycline Suppressing MMP9 activity Rat hemorrhagic cerebral infarction model Murata et al. [31]
NXY-059 Scavenging free radicals Rabbit hemorrhagic cerebral infarction model Lapchck et al. [32]
Edaravone Scavenging free radicals Rat hemorrhagic cerebral infarction model Yamashita et al. [23]
Ischemia / reperfusion Exogenous tPA
Activation of MMP-9
Vascular endothelial cell injury
IL-1ｹ, TNFｸ↑ Free radicals↑
LRP PAR1
NF-κｹ↑
Degradation of extracellular matrix
BBB disruption / hemorrhage
NXY-059
Edaravone
APC
BB-94
Fig. 2　 Possible mechanism of vascular unit disruption after ischemia and reperfusion with tPA.  MMP-9 can disrupt the BBB by degrad-
ing the basal membrane/extracellular matrix proteins,  thereby leading to BBB leakage and hemorrhaging.  In the acute phase of a stroke,  
MMP-9 can be activated by pro-inﬂammatory factors (e.g.,  IL-1β,  and TNF-α) and free radicals.  In addition,  the tPA that is administered 
strongly activates MMP-9 through multiple pathways.  MMP-9 activation is inhibited by several reagents: NXY-059,  edaravone,  APC and 
BB-94 (Table 1).
enger,  edaravone,  in preventing HT.  Administration 
of tPA alone signiﬁcantly worsened the survival rate 
compared with those rats treated with vehicle.  On the 
other hand,  treatment with edaravone plus tPA sig-
niﬁcantly increased the survival rate,  improved motor 
function,  and dramatically decreased HT.  We also 
demonstrated that treatment with edaravone sup-
pressed MMP-9 expression at and around cerebral 
microvessels,  inhibited the degradation of basement 
membrane protein,  and prevented the microvessels 
from dissociating.  These results suggested that 
edaravone can protect cerebral microvascular integ-
rity,  because it safeguards the basement membrane 
from excess free radicals and MMP-9,  leading to a 
subsequent decrease in HT and improvement in the 
survival rate and neurological outcome [23].
　 In a clinical trial,  edaravone attenuated the result-
ing disability in humans 90 days after acute ischemic 
stroke without serious adverse events [24],  and it has 
been used clinically in Japan as a neuroprotective 
agent for acute stroke patients since 2001.  In a large 
clinical trial,  another free radical scavenger,  NXY-
059,  initially seemed to reduce disability after stroke 
[25],  but this eﬀect could not be reproduced [26].  
Nonetheless,  one other characteristic of NXY-059 
was its potential to inhibit symptomatic HT after tPA 
treatment [25].  NXY-059 is water soluble (octanol/
water partition coeﬃcients; cLog p＝－2.09).  In 
contrast,  edaravone has a biphasic,  water-soluble,  
and lipid-soluble nature (cLog p＝1.33),  and it has 
been reported that it is able to easily pass through the 
BBB to enter the brain parenchyma and cerebral ﬂuid 
[27].  As the site most vulnerable to free radical dam-
age is on the outer side of the vascular endothelium 
(e.g.,  the basal membrane),  this unique chemical prop-
erty of edaravone might be an advantage for its 
delivery to the basement membrane.  Therefore,  com-
bination therapy with edaravone and tPA is a promis-
ing therapeutic strategy for acute stroke patients,  not 
only in reducing infarct size but also in minimizing 
catastrophic HT.
　 In this article,  we brieﬂy highlighted recent prog-
ress in the development of new therapeutic strategies 
for vascular protection in the post-stroke brain.  To 
realize more eﬀective therapies for patients suﬀering 
from stroke,  it is important to combine these strate-
gies in the acute phase following a stroke.
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